Abstract Library

#4199 Unravelling the RNA landscape of small intestine neuroendocrine neoplasms applying transcriptomic and spliceosomic perspectives

Introduction: The study of small intestine neuroendocrine neoplasms (siNENs) transcriptomics represents a challenge due to their rarity, tissue availability, and heterogeneity. Recent studies identified different molecular subtypes, but there are still gaps in the molecular mechanisms driving siNEN progression.

Conference:

Presenting Author:

Authors: Ibáñez-Costa A, Pedraza-Arevalo S, Moreno-Montilla M, Hernando J, García A,

Keywords: small intestine neuroendocrine neoplasm, splicing, transcriptomics, biomarker,

#3184 Immune heterogeneity and cascade of changes in subtypes of pancreatic neuroendocrine tumors

Introduction: Previously, we published four molecular subtypes of pancreatic neuroendocrine tumors (PanNETs) - met-like primary (MLP)-1 and -2, intermediate and insulinoma- like with different clinical and molecular characteristics. While immunotherapy trials are on-going in PanNETs, the immune landscape of this disease is largely unknown.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Sadanandam A

Authors: Sadanandam A, Young K, Lawlor R, Ragulan C, Patil Y,

Keywords: pancreatic neuroendocrine tumor, immune microenvironment, viral-mimicry pathway, pancreatic cancer, computational methods, T cells, macrophages, immunotherapy, B cells, complement pathway, interferon signalling, STING pathway, hypoxia, necroptosis, tumor ,

#2963 Intrinsic Gene Programs in Metastasis-like Primary Subtype Is Associated with Early Metastatic Evolution in Pancreatic Neuroendocrine Tumours

Introduction: Three molecular subtypes of pancreatic neuroendocrine tumours (PanNETs) have been described: insulinoma-like, intermediate and metastasis-like primary (MLP). The Latter is a non-functional tumours with highly metastatic potential. A mouse model of PanNET showed that MLP subtype has two different pathways of progression including stem/progenitor and epithelial-to-mesenchymal transition. However, the evolution of metastasis in patients requires further studies.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Sadanandam A

Authors: Sadanandam A, Lawlor R, Nyamundanda G, Ragulan C, Scarpa A,

Keywords: Pancreatic neuroendocrine tumors, metastasis, metastatic evolution, early metastasis, recurrence, prognosis, Patient tumours, cause and effect relationship, computational modeling, molecular subtypes, stages, metastatic potential,

#2745 Integrative Genomic Characterization Identifies Molecular Subtypes of Lung Carcinoids

Introduction: Lung carcinoids (LCs) are rare and slow growing primary lung neuroendocrine tumors. The WHO classify LCs into atypical and typical carcinoids. Recent studies have shown that the reproducibility of LCs classification and its prognostic efficacy have high interobserver variability

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Laddha S

Authors: Laddha S, da Silva E, Robzyk K, Untch B, Ke H,

Keywords: MEN1, Lung Carcinoid, Lung Cancer, ASCL1, Novel Molecular Subtypes, Genotype to Phenotype, Integrative Genomic Analysis, Biomarkers, Genomics and Epigenomics,

#2215 Development of Multiplex Biomarker Assay to Subtype Pancreatic Neuroendocrine Tumors (PanNETs) with Distinct Prognosis and Mutations

Introduction: Overall 5-year survival for PanNETs ranges from 25-100%. The treatment paradigm for PanNETs largely based upon grades, which is significantly heterogeneous. We previously defined three molecular subtypes (distributed grades) of PanNETs using PanNETassigner signature. There is an unmet clinical need for prognostic and predictive biomarkers and clinically-relevant assays to complement grade and improve patient stratification.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Sadanandam A

Authors: Sadanandam A, Young K, Nyamundanda G, Ragulan C, Lawlor R,

Keywords: molecular subtypes, biomarker assay, clinical assay, patient prognosis, subtype-specific mutations, NanoString Technologies, low-cost assay, pancreatic neuroendocrine tumors, grades, PanNETassigner subtype, patient stratification, pnet,